76 results about "Phospholipid complex" patented technology

The invention discloses a preparation method of an oral liver protection composition containing ergothioneine, and relates to the technical field of ergothioneine application. The oral liver protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.5 to 5 parts of the ergothioneine, 10 to 30 parts of silibinin, 20 to 50 parts of a phospholipid complex, 5 to 15 parts of a liver targeting carrier, 2 to 8 parts of a disintegrating agent, 1 to 5 parts of an adhesive and 2 to 4 parts of an antioxidant. Free radicals are efficiently captured through a polycyclic conjugated pi electron system of the antioxidant, a hydrogen bond network is formed by a heteroatom bridging effect of the antioxidant, a galactose group of the liver targeting carrier and the disintegrating agent, and the stability of the system is synergistically improved; the phospholipid complex is embedded with a hydrophobic drug and a hydrophilic carrier, and the drug is accurately delivered to the liver by combining the specific recognition capability of the liver targeting carrier; the ergothioneine and the silybin form a bidirectional synergistic liver protection mechanism by removing reactive oxygen free radicals and regulating and controlling cell signal channels respectively.

The invention belongs to the technical field of medicines, and particularly provides a solid dispersion as well as a preparation method and application thereof. The solid dispersion comprises a carrier material, and further comprises quercetagetin and phospholipid, the mass ratio of the quercetagetin to the phospholipid is 1: (0.3-1.5), and the carrier material comprises one or more of a hydrophilic polymer and a pH-dependent polymer. Wherein the quercetagetin and the phospholipid are combined through an intermolecular force, so that the quercetagetin obtains a lipid material similar to a cell membrane structure, a cell membrane bionic phospholipid compound is formed, the cell membrane bionic phospholipid compound can be naturally compatible with an upper wall cell membrane of a small intestine, and the permeation transmembrane capability of the quercetagetin is better promoted; the quercetagetin is added into the solid dispersion, so that more quercetagetin can enter systemic circulation and lymphatic circulation, and therefore, the solid dispersion can strengthen transmembrane absorption while strengthening dissolution, so that the solid dispersion has high bioavailability.

The invention relates to the technical field of food sustained-release preparations, and particularly discloses a sour cherry powder sustained-release preparation with a stable uric acid reducing effect and a preparation process of the sour cherry powder sustained-release preparation. The sour cherry powder sustained-release preparation comprises a core active phase freeze-dried sour cherry powder, a sustained-release carrier phase, a synergistic function phase, an auxiliary regulation phase and a filler, the synergistic functional phase contains a celery seed extract, a curcumin-phospholipid complex, a prebiotic complex and the like, and all the components have a synergistic effect. The preparation method comprises the following steps: carrying out wall breaking, enzymolysis, purification and freeze-drying treatment on sour cherry fruits to obtain a core raw material, compounding the core raw material with other components, and carrying out slow-release carrier construction, coating granulation and other steps to prepare the microcapsule structure preparation. The preparation can be used for assisting in reducing the uric acid level, and has the advantages of high stability of active ingredients, continuous and stable uric acid reducing effect, consideration to intestinal health and the like; the preparation process adopts freeze-drying and micro-capsule coating technologies, effectively retains active ingredients, is controllable in operation, and is suitable for large-scale production.

The application relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition comprises 35-45 parts of a cyclodextrin inclusion compound, 25-35 parts of nano-liposomes, 20-30 parts of a chicory extract-phospholipid complex and 5-8 parts of an antioxidant complex; the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding pueraria extract, drying after inclusion reaction, and obtaining inclusion compound a; step 2, adding hydroxypropyl-gamma-cyclodextrin into water, stirring, adding mulberry leaf extract, drying after inclusion, and obtaining inclusion compound b; and step 3, mixing the inclusion compound a and the inclusion compound b, and obtaining the product. The uric acid reducing composition can more comprehensively and efficiently reduce blood uric acid level, and has high safety, high stability and high bioavailability. The preparation method is simple, easy to industrialize and beneficial to large-scale industrial production.

The invention discloses a method for improving the water-retaining property of meat paste, which specifically comprises the following steps: firstly, sufficiently tumbling and chopping fresh meat paste to be treated at low temperature, and adjusting the pH value of the meat paste to be neutral; then, protein-phospholipid composite emulsion is added into the meat paste, the protein-phospholipid composite emulsion is prepared by mixing phospholipid extracted from livestock and poultry head tissues, a carrier protein solution and algal polysaccharides, then mixing the mixture with edible oil, performing ultrasonic treatment, emulsifying and homogenizing, and finally, a small amount of the protein-phospholipid composite emulsion is added into the pretreated meat paste for many times, and homogenizing at high pressure, adding transglutaminase, and packaging in vacuum. The method is simple, the steps are easy to operate, the pH value of the meat paste can be reduced, the loss rate of juice in the meat paste can be reduced, the water-retaining property of the meat paste can be improved, and meanwhile, the structural stability of the meat paste can be enhanced by improving the combination of fat and water.

A preparation method of the whey protein isolate-phospholipid complex embedded fucoxanthin emulsion comprises the following steps: (1) mixing and homogenizing phosphatidyl glyceride and a buffer solution to obtain a phospholipid emulsion, and the phosphatidyl glyceride is selected from DHA (docosahexaenoic acid) phosphatidyl glycerol monocaprylate, DHA phosphatidyl glycerol monocaprylate and the like; the phospholipid emulsion and the whey protein isolate solution are mixed and homogenized, and whey protein isolate-phospholipid compound O / W emulsion is obtained; and (2) dropwise adding the fucoxanthin solution into the whey protein isolate-phospholipid compound O / W emulsion, and stirring to obtain the fucoxanthin emulsion. The whey protein isolate-phospholipid compound embedded fucoxanthine emulsion disclosed by the invention is good in stability, high in encapsulation efficiency, excellent in oxidation resistance and high in bioavailability of fucoxanthine, and the particle size of the emulsion is 200 nm or less. According to the research, the application of the novel phospholipid in the aspect of stable emulsion system construction is expanded, and a new thought and direction are provided for embedding and delivery of active substances.

The present invention relates to the field of plant extract processing, and particularly to a preparation method of silymarin phospholipid complex and a special stirring reactor therefor. In a preparation method of silymarin phospholipid complex of the present invention, by controlling the specification / addition ratio of phospholipids in the same process, after complexing with silymarin, water precipitation is carried out, and water-soluble impurities in the raw materials are separated and removed while preparing the silymarin phospholipid complex, further increasing the content of active ingredients. A special stirring reactor for preparing silymarin phospholipid complex of the present invention has three functions of successively completing the stirring and mixing treatment of two kinds of liquid materials, the filtration treatment of precipitation and solvent, and the drying and pulverizing treatment of precipitation, realizing that multiple treatment processes are completed by one machine, saving the time consumed by material transfer in each treatment step and the equipment operation cost, and greatly improving the production efficiency of silymarin phospholipid complex.

A cleaning composition including a preservative formulation having a lactic acid salt, a gluconic acid salt, a polyhydric alcohol and optionally a phospholipid complex is disclosed. The cleaning composition can be loaded on a cleaning wipe and used for personal care. The lactic acid salt, gluconic acid salt and polyhydric alcohol provide a synergistic preservative effect to a cleaning composition incorporating the preservative formulation.

The invention relates to an ophthalmic antifungal phospholipid complex solution containing posaconazole. The ophthalmic antifungal phospholipid complex solution comprises at least one of an anionic phospholipid complex solution, a neutral phospholipid complex solution and a cationic phospholipid complex solution, when the solution is an anionic phospholipid complex solution, the posaconazole, phospholipid, beta-sitosterol, a hydrated buffer solution and an organic solvent are mixed according to a ratio of 10 mg of posaconazole, 20-200 mg of phospholipid, 20-120 mg of beta-sitosterol, 5-20 mL of the hydrated buffer solution and 1-20 mL of the organic solvent; when the solution is a neutral phospholipid complex solution, the posaconazole and phospholipid complex solution is prepared from the following components in proportion: 10 mg of posaconazole, 17.5 to 170 mg of phospholipid, 20 to 120 mg of beta-sitosterol, 2.5 to 30 mg of DSPE-PEG2000, 5 to 20 mL of hydrated buffer solution and 1 to 20 mL of organic solvent; when the solution is a cationic phospholipid complex solution, the following components are proportioned: 10 mg of posaconazole, 17.5 to 170 mg of phospholipid, 20 to 120 mg of beta-sitosterol, 2.5 to 30 mg of DSPE-PEG2000, 20 to 70 mg of a cationic material, 5 to 20 mL of a hydration buffer solution and 1 to 20 mL of an organic solvent. The penetrating power of the phospholipid complex solution in cornea can be remarkably improved, and the effect of treating fungal keratitis is remarkable.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.

A cyclocurcumin-based composition consisting of: a cyclocurcumin component present at 20 to 40 wt% of the total composition; a curcuminoid component present at 30 to 50 wt%, comprising 20 to 30 wt% curcumin, 5 to 10 wt% demethoxycurcumin, and 3 to 8 wt% bisdemethoxycurcumin; a solubilizer component present at 5 to 15 wt%, comprising polysorbate at 3 to 8 wt% and lecithin at 3 to 7 wt%; a complexing component present at 5 to 12 wt%, comprising cyclodextrin inclusion complexes; and a nanoparticulate component present at 3 to 10 wt%, comprising cyclocurcumin particles with a particle size in the range of 50 nm to 200 nm. consists of a polymer stabilizing component, which is present in an amount of 4 to 10 wt.-% is present and comprises polyvinylpyrrolidone or polyethylene glycol, a phospholipid complex component present in an amount of 3 to 8 wt% and consisting of phosphatidylcholine complexes, and an encapsulation component present in an amount of 2 to 6 wt% and containing maltodextrin or gum arabic, the composition being configured to ensure improved solubility, stability and bioavailability.

The invention provides a resorcinol derivative phospholipid complex dispersion as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. A resorcinol derivative, an antioxidant, lecithin, sodium surfactin and water are used as raw materials, a strongly hydrophobic phospholipid compound is formed through interaction between hydrophilic ends of the lecithin and strong molecules of phenolic hydroxyl groups of the resorcinol derivative, then a hydrophilic cyclopeptide layer is modified on the surface of the phospholipid compound through the sodium surfactin surfactin, and the hydrophobic phospholipid compound is prepared. The dispersity of the phospholipid complex in water is improved, the stability of the resorcinol derivative can be effectively improved, and the problem of high-temperature discoloration is avoided. The particle size of the resorcinol derivative phospholipid complex dispersion provided by the invention is less than 200nm, and the resorcinol derivative phospholipid complex dispersion has good hydrophilicity and better transdermal permeation absorption effect.

The invention relates to the field of mixture three-phase separation, and provides a shipborne three-phase separation recycling system and method.The system comprises the steps that a horizontal spiral centrifugal machine conducts three-phase separation on a fed euphausia superba solid-liquid mixture, and a first solid-phase output matter, a first liquid-phase output matter and a first oil-phase output matter are obtained; the disc centrifuge performs three-phase separation on the first liquid phase output substance and a third liquid phase output substance from the extruder to obtain a second solid phase output substance, a second liquid phase output substance and a second oil phase output substance, wherein the second solid phase output substance, the second liquid phase output substance and the second oil phase output substance are obtained from the second oil phase output substance; the first solid-phase output matter and the second solid-phase output matter are compressed, sheared and dewatered by the extruding machine, and a target euphausia superba solid matter and a third liquid-phase output matter are obtained; the heat exchange flocculation assembly is used for heating, flocculating and filtering the second liquid phase output substance to obtain the target protein phospholipid complex. The target protein phospholipid complex is obtained by fully utilizing the liquid-phase output substance, and the utilization rate is increased.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

The invention belongs to the technical field of pharmacy, and particularly relates to minoxidil liniment and a preparation method thereof. According to the minoxidil liniment disclosed by the invention, the nano-liposome prepared from the lichen extract-phospholipid complex is used for wrapping minoxidil, the common allergic dermatitis phenomenon in the using process of the minoxidil liniment is avoided by utilizing a synergistic drug loading mechanism of the lichen extract and the phospholipid complex and through anti-inflammatory and anti-oxidation effects, and meanwhile, the drug structure is protected; the action time of the minoxidil liniment is prolonged; the gel substance formed by the polyvinyl alcohol-sodium carboxymethyl cellulose composite coating liquid reduces the surface exposure of minoxidil, avoids the precipitation of minoxidil crystals, and ensures the delivery and absorption efficiency of minoxidil drugs.

The application discloses an anti-aging ergothioneine and nicotinamide compound preparation and a preparation method and application thereof, and belongs to the technical field of cosmetic health products. The compound preparation takes pyrroloquinoline quinone, ergothioneine and nicotinamide as the core, and is matched with betaine, trehalose, quercetin phospholipid complex, alpha-lipoic acid and N-acetyl cysteine in specific proportions. The anti-aging ergothioneine and nicotinamide compound preparation and the preparation method and application thereof are adopted, the components such as PQQ, ergothioneine, nicotinamide and quercetin phospholipid complex are synergistically used, and the synchronous activation of mitochondrial regeneration, energy metabolism, free radical targeted removal and mitochondrial mass control is realized for the first time. The compound preparation can be prepared into cosmetics for external use on the skin, and the effects of antioxidation and skin barrier repair can be achieved.

The invention belongs to the technical field of biological medicine preparation, and particularly discloses a preparation method of a curcumin-butylphthalide-phospholipid complex, which comprises the following steps: dissolving curcumin, butylphthalide and lecithin in an organic solvent A, carrying out mixed reaction in a water bath, removing the organic solvent A after the mixed reaction is finished, and purifying by adopting an organic solvent B to obtain the curcumin-butylphthalide-phospholipid complex. And removing the organic solvent B, so as to obtain the curcumin synergistic butylphthalide phospholipid compound. The invention relates to a preparation method of nanoparticles of a curcumin synergistic butylphthalide phospholipid compound, which comprises the following steps: dissolving the curcumin synergistic butylphthalide phospholipid compound in deionized water, oscillating in a water bath to fully dissolve, and filtering through a microfiltration membrane to obtain the nanoparticles of the curcumin synergistic butylphthalide phospholipid compound. Through the synergistic effect of curcumin and butylphthalide, the treatment effect on nervous system diseases is remarkably improved, and a new thought and strategy are provided for treatment of nervous system diseases.

The invention relates to the field of traditional Chinese medicine synthesis and preparation, in particular to a preparation device and method of a silybum marianum phospholipid complex. According to the preparation method of the silybum marianum phospholipid complex, the preparation device of the silybum marianum phospholipid complex is used, the steps of compounding treatment, filtering and drying are optimized, the compounding rate of the prepared silybum marianum phospholipid complex is increased, and the yield of the silybum marianum phospholipid complex is improved. The prepared silybum marianum phospholipid complex product has the advantages of low solvent residue and good water solubility and fat solubility, in addition, on the basis of completing two different filtering treatment in sequence, the silybum marianum phospholipid complex can be rapidly switched to a drying treatment mode after completing the second filtering treatment, the steps of the silybum marianum phospholipid complex preparation treatment process are reduced, and the production cost is reduced. The preparation process is simple, low in cost and suitable for industrial production, the technical defects that the preparation steps of the silybum marianum phospholipid complex are complex and tedious, and the preparation treatment efficiency is poor are greatly overcome, and the preparation work efficiency of the silybum marianum phospholipid complex is improved.

The invention provides a micro-fat calcium supplement carrier, which is prepared from the following raw materials in parts by weight: 30 to 35 parts of standard index calcium, 1 to 5 parts of chondroitin, 1 to 5 parts of glucosamine, 8 to 12 parts of pure camel milk, 0.7 part of vitamin D, 2 to 70.3 parts of vitamin K, 1 to 3 parts of phospholipid complex and 8 to 10 parts of excipient. According to the invention, standard calcium, chondroitin, glucosamine, pure camel milk, vitamin D, vitamin K2-7, a phospholipid complex and an excipient are organically mixed by adopting a liposome carrier technology, so that the digestion and absorption of calcium in a body and the distribution of calcium in a specific region are effectively improved, and further the effects of rapid bone growth, increase of bone length (promotion of height increase) and increase of bone density are achieved; the health-care food has the health-care functions of reducing the fracture probability, preventing tooth decay, reducing the death rate of cardiovascular diseases and the like, so that the calcium absorption rate is remarkably improved and reaches up to 95%.

The invention belongs to the technical field of food processing, and particularly relates to stable type long-acting auxiliary lipid-lowering camellia diester edible oil and a preparation method of the stable type long-acting auxiliary lipid-lowering camellia diester edible oil. Comprising the following preparation raw materials in parts by mass: 25 to 30 parts of composite camellia diester oil, 3 to 5 parts of a blood fat reducing compound, 0.3 to 0.5 part of disodium ethylene diamine tetraacetate, 0.2 to 0.4 part of a theine phospholipid compound, 0.3 part of phytosterol, 0.5 to 1 part of royal jelly, 0.1 part of lemon oil, 0.05 part of inulin and 0.3 to 0.6 part of algae oil. The stable long-acting auxiliary lipid-lowering camellia diester edible oil provided by the invention realizes lipid-lowering-stabilization-nutrition three-dimensional balance: multi-component synergistic lipid-lowering, constructs an anti-oxidation system to guarantee stability, synchronously optimizes nutrition synergy and component activity, and realizes multi-component synergism.

The invention relates to a quality control method for indissolvable impurities in preparation of esdoxaban tosylate, and belongs to the field of pharmaceutical analys.The quality control method comprises the steps that the indissolvable impurities and phospholipid are mixed to prepare a phospholipid compound; dissolving the phospholipid complex in a solvent to obtain a test solution; the indissolvable impurity is N, N '-bis (5-chloropyridine-2-yl) oxadiamide; and detecting the test solution by using a high performance liquid chromatography. According to the invention, a pretreatment method is creatively adopted, phospholipid is taken as a carrier, and insoluble impurities and phospholipid are co-ground, so that the dissolution barrier is effectively reduced on the premise that the original structure of the compound is not damaged, and rapid and thorough dissolution is realized. The process is mild and controllable, the chemical stability of the compound can be kept, the detectable level of the impurity is greatly improved, and meanwhile the problem that the impurity is poor in solubility in a conventional solvent and quality control is difficult to effectively conduct is solved.

The present invention provides an edible composition for alleviating visual fatigue. The composition comprises in parts by weight 1 to 10 parts of curcuma powder, 1 to 12 parts of whole coffee fruit extract, 1 to 20 parts of phospholipid composite, 1 to 15 parts of DHA, 0.5 to 5 parts of phosphatidylserine, and 0.1 to 5 parts of vitamin C. After one week of trial consumption by the subject, the duration of photopic vision is improved with a significant difference in comparison with that before the trial; after 2 weeks of trial consumption, the overall score of visual fatigue symptoms decreases with a significant difference in comparison with that before the trial; after 8 weeks of trial consumption by the subject, the vision field thereof is remarkably enlarged, indicating the formulation may prevent the occurrence of glaucoma. The coffee extract combined with the remaining ingredients has a synergistic effect.

The invention relates to the technical field of biological substance preparation. The invention provides a catechin-phospholipid complex and an emulsion prepared from the catechin-phospholipid complex and capable of improving DHA (docosahexaenoic acid) and improving memory activity. The invention also provides an application of the catechin-phospholipid complex or the emulsion for improving the memory activity of DHA in preparation of health-care products. The emulsion prepared by adopting the catechin-phospholipid compound as an emulsifier can efficiently and synergistically entrap, stably protect and deliver the beta-carotene and the DHA in a targeted manner, so that the bioavailability and the multi-component synergistic effect of the beta-carotene and the DHA are enhanced, and the effect of improving the memory function is realized; meanwhile, good physical and chemical stability and digestion tolerance are also shown.

The invention belongs to the technical field of biology, and particularly relates to a sialic acid derivative-modified zebrutinib phospholipid complex as well as a preparation method and application thereof, the sialic acid derivative-modified zebrutinib phospholipid complex comprises zebrutinib, phospholipid and a sialic acid derivative, and the medicine-lipid ratio of the zebrutinib to the phospholipid is (2: 1)-(1: 10) (n / n). The addition proportion of the sialic acid derivative accounts for 5-40% of the total molar weight of substances. The sialic acid derivative-modified zebrutinib phospholipid complex can be used for preparing a nano injection and improving the in-vivo targeting capability and the tumor treatment effect. Especially, lasting and effective immune memory ability on tumor cells is established in a mouse body, anti-tumor immune response of the body can be more effectively activated and maintained, and secondary tumor-bearing challenge is successfully resisted.

The present invention discloses a forsythiaside phospholipid complex and its preparation method and application, which belong to the field of medical technology. The forsythiaside phospholipid complex includes forsythiaside and phospholipid, and its preparation method includes dissolving a certain proportion of forsythiaside and phospholipid in an organic solvent and stirring the reaction in a constant temperature water bath, and then subjecting the reaction solution to reduced pressure rotary evaporation and vacuum drying to obtain the forsythiaside phospholipid complex. The forsythiaside phospholipid complex prepared by the present invention can be prepared as an oral preparation on the one hand to improve oral bioavailability and drug distribution in lung tissue, and on the other hand, it can be prepared into a suspension by hydration, and the drug can be delivered to the lungs by intravesical instillation to treat interstitial cystitis, or delivered to the lungs by atomized inhalation to prolong the lung residence time and lung drug exposure. Compared with conventional original drug preparations, the forsythiaside phospholipid complex of the present invention significantly improves the efficacy of treating interstitial cystitis and the anti-inflammatory effect of inflammation caused by lung infection viruses and bacteria.

The invention discloses a silybum marianum lipidosome applied to a liver protection tablet product and a preparation method, the silybum marianum lipidosome comprises a core material, and an internal wall material and an external wall material which sequentially wrap the surface of the core material; the core material is a silybum marianum extract; the inner wall material is modified soybean phospholipid; the outer wall material is a combination of starch sodium octenylsuccinate and polyethylene glycol. A lipidosome membrane embedding technology is adopted, the silybum marianum extract and soybean modified phospholipid are mixed according to a certain proportion and emulsified into a membrane, phospholipid bimolecular membrane embedding is formed, and then high-molecular compounds including starch sodium octenylsuccinate and polyethylene glycol are used as external wall materials to further include the phospholipid compound of the silybum marianum extract. The prepared lipidosome can be uniformly dispersed in an aqueous solution, the angle of repose is less than or equal to 40 degrees, the fluidity and the tabletting effect are better, the lipidosome is prepared into a sustained-release tablet, the bioavailability of the lipidosome can be improved, and the application of the lipidosome in a liver protection factor system can be expanded.

The invention belongs to the technical field of biological medicines, and particularly relates to all-trans retinoic acid phospholipid complex nanoparticles as well as a preparation method and application thereof. The invention relates to sialic acid derivative modified all-trans retinoic acid and phospholipid compound nanoparticles. The sialic acid derivative modified all-trans retinoic acid and phospholipid compound nanoparticles comprise sialic acid derivatives, all-trans retinoic acid and phospholipid, wherein the sialic acid derivative accounts for 5-40% of the total mass of the phospholipid, and the drug-lipid molar ratio of all-trans retinoic acid to the phospholipid is (1: 4)-(1: 10). According to the sialic acid derivative modified all-trans retinoic acid phospholipid complex nanoparticles, the problem that all-trans retinoic acid is poor in solubility is solved, the bioavailability of an existing all-trans retinoic acid oral product is improved, the tumor inhibition effect of all-trans retinoic acid in solid tumors is improved, and the bioavailability of all-trans retinoic acid is improved. And the drug resistance of all-transretinoic acid in solid tumors is overcome. The nano preparation is simple and convenient in process, high in reproducibility and convenient for industrial production. In addition, a combined treatment strategy of the nano preparation and a low-dose chemotherapeutic drug shows a very excellent synergistic effect, which is shown as a tumor healing condition.

The application belongs to the technical field of pharmacy, and particularly relates to a minoxidil liniment and a preparation method thereof. The application wraps minoxidil by using a lichen extract-phospholipid complex to prepare nano-liposomes, utilizes the synergistic drug loading mechanism of the lichen extract and the phospholipid complex, avoids the common allergic dermatitis phenomenon in the use process of the minoxidil liniment through anti-inflammatory and antioxidant effects, protects the drug structure, and prolongs the action time of the minoxidil liniment; the gel-like substance formed by using a polyvinyl alcohol-carboxymethylcellulose sodium complex coating solution reduces the surface exposure of minoxidil, avoids the precipitation of minoxidil crystals, and guarantees the delivery and absorption efficiency of minoxidil drugs.